Qiangnao Technology: Dozens of humanoid robot companies have placed orders, and sales of bionic hands are expected to increase significantly this year.
Bionic hand manufacturer Strongbrain Technology is experiencing a surge of orders brought by the explosion of the humanoid robot industry.
According to Bloomberg, He Xiyujin, partner of Strongbrain Technology, said in an interview that dozens of robot companies, including Unitree Robotics and Leju Robotics, have begun purchasing the company’s five-finger bionic hands.
He Xiyujin pointed out that Chinese humanoid robot companies are shifting their focus from technical demonstrations to finding practical application scenarios. This trend is rapidly driving demand. The bionic hand business of Strongbrain Technology “has shown significant growth compared to last year.”
The urgent demand for dexterous hands in the humanoid robot industry is attracting increasing attention from capital. Competition and financing activities in this sector are heating up simultaneously, and Strongbrain Technology itself has also secretly submitted an IPO application in Hong Kong.
Humanoid Robot Demand Drives Surge in Bionic Hand Orders
Strongbrain Technology initially focused on brain-computer interface (BCI) technology, developing bionic prosthetic hands that amputees or disabled individuals could control via EEG signals, enabling users to perform fine movements such as playing the piano or practicing calligraphy. Now, this technology is being adopted on a large scale by the humanoid robot industry.
He Xiyujin stated that Chinese humanoid robot companies are moving from “spectacle demonstrations” toward exploring the genuine real-world value of robots. Five-finger dexterous hands, which can grasp and manipulate objects like human hands, are one of the key hardware components for achieving this goal. Musk has referred to this as the “hand problem” faced by humanoid robots—how to enable mechanical hands to match the precision and flexibility of human hands remains one of the industry’s core challenges.
Sector Financing Heats Up, Multiple Enterprises Seek IPOs
The commercial value of the dexterous hand sector is widely recognized by the capital market. According to a Bloomberg report in May, Chinese company Linkerbot, which holds over 80% of the global dexterous robot hand market, is considering launching an IPO after completing 1.5 billion RMB (about $220 million USD) in financing.
In terms of listing progress, Unitree Robotics’ IPO has been approved by regulators; according to insiders, Strongbrain Technology has also secretly submitted a Hong Kong IPO application.
Nvidia has announced that its chips will provide computing power to a reference robot model, which combines Unitree Robotics’ H2 Plus humanoid robot with Singapore AI robot company Sharpa’s five-finger hand.
BCI and Embodied Intelligence Integration Is the Future Direction
Strongbrain Technology positions itself as a comprehensive platform in the brain-computer interface field, rather than simply a bionic hand manufacturer. The company is also developing head-worn devices that use BCI technology to intervene in neurological disorders such as autism, ADHD, and insomnia, and is working on a BCI treatment solution aimed at replicating the appetite-suppressing effect of GLP-1 weight-loss drugs, expected to be launched between the end of 2027 and 2028.
“We’re not just making hands,” He Xiyujin said, “We believe BCI and embodied intelligence can be integrated. Robots controlled by the human brain will be an important future direction.”
Strongbrain Technology is one of several Chinese brain-computer interface startups seeking to challenge leading US companies such as Neuralink. As the humanoid robot industry accelerates toward commercialization, the strategic value of this niche sector is becoming increasingly evident.
Risk Warning and DisclaimerThe market involves risks, investment requires caution. This article does not constitute personal investment advice, nor does it consider the individual investment objectives, financial situation, or needs of specific users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their particular circumstances. Invest accordingly at your own risk.